

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)  
154<sup>th</sup> Meeting of the Vaccines and Related Biological Products Advisory  
Committee  
FDA White Oak Campus, Building 31, Great Room  
Salon B & C  
Silver Spring, MD  
November 8, 2018**

**AGENDA  
Meeting Link:**

<https://collaboration.fda.gov/vrbpac1118/>

**Topic :** Presentation of the Laboratory of DNA Viruses (LDV), Division of Viral Products (DVP), Office of Vaccine Research and Review (OVR), Center for Biologics Evaluation and Research (CBER)

**Note:** Committee members are participating via teleconference

Time	Presentation/Presenter
<b>11:00 AM</b>	<b>Opening Remarks: Call to Order, Introduction of Committee</b> Arnold Monto, M.D. Acting Chair, VRBPAC  <b>Administrative Announcements, Conflict of Interest Statement</b> Serina Hunter-Thomas, M.S.A., R.N. Designated Federal Officer, VRBPAC CBER, FDA
<b>11:15 AM</b>	<b>Overview of Research/Site Visit Process, CBER (15 min)</b> Carolyn Wilson, Ph.D. Associate Director for Research CBER/FDA
<b>11:30 AM</b>	<b>Overview of DVP (15 min)</b> Jerry Weir, Ph.D. Director, Division of Viral Products Office of Vaccines Research and Review
<b>11:45 AM</b>	<b>Overview of LDV (15 min)</b> Keith Peden, Ph.D. Principal Investigator Laboratory of DNA Viruses CBER/FDA/OVR/DVP
<b>12:00 PM</b>	<b>Break (15 min)</b>
<b>12:15 PM</b>	<b>Open Public Hearing (60 min)</b>
<b>1:15 PM</b>	<b>Conflict of Interest Statement (5 min)</b> Serina Hunter-Thomas, M.S.A., R.N. Designated Federal Officer VRBPAC
<b>1:20 PM</b>	<b>Closed Session (50 min)</b>
<b>2:10 PM</b>	<b>Adjourn Meeting</b>